US20230346899A1 - PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 - Google Patents
PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 Download PDFInfo
- Publication number
- US20230346899A1 US20230346899A1 US18/298,056 US202318298056A US2023346899A1 US 20230346899 A1 US20230346899 A1 US 20230346899A1 US 202318298056 A US202318298056 A US 202318298056A US 2023346899 A1 US2023346899 A1 US 2023346899A1
- Authority
- US
- United States
- Prior art keywords
- sars
- cov
- infection
- apr
- present application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title claims abstract description 82
- 108010039627 Aprotinin Proteins 0.000 title claims abstract description 79
- 229960004405 aprotinin Drugs 0.000 title claims abstract description 65
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 230000002265 prevention Effects 0.000 title claims abstract description 21
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 title claims abstract description 20
- 229940125674 nirmatrelvir Drugs 0.000 title claims abstract description 14
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 12
- 208000015181 infectious disease Diseases 0.000 title abstract description 23
- 238000002648 combination therapy Methods 0.000 title abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
- 229960000311 ritonavir Drugs 0.000 claims description 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 6
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 claims description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000003612 virological effect Effects 0.000 abstract description 10
- 201000001178 Bacterial Pneumonia Diseases 0.000 abstract 1
- 206010035737 Pneumonia viral Diseases 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 208000009421 viral pneumonia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 54
- 229940079593 drug Drugs 0.000 description 48
- 241000700605 Viruses Species 0.000 description 30
- 210000004072 lung Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 108010079099 gordox Proteins 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 101100379068 Caenorhabditis elegans apc-2 gene Proteins 0.000 description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 241000699800 Cricetinae Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940125675 paxlovid Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940108519 trasylol Drugs 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 6
- -1 inhalation Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 108010027490 Antagosan Proteins 0.000 description 5
- 101100438971 Caenorhabditis elegans mat-1 gene Proteins 0.000 description 5
- 241000699673 Mesocricetus auratus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000006199 nebulizer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108060005987 Kallikrein Proteins 0.000 description 4
- 102000001399 Kallikrein Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- AXTADRUCVAUCRS-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrole-2,5-dione Chemical compound OCCN1C(=O)C=CC1=O AXTADRUCVAUCRS-UHFFFAOYSA-N 0.000 description 2
- 101800000504 3C-like protease Proteins 0.000 description 2
- 229940125673 3C-like protease inhibitor Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 2
- 101800000596 Probable picornain 3C-like protease Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 2
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000013504 emergency use authorization Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 229950008454 favipiravir Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000026425 severe pneumonia Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000015474 Central precocious puberty Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 1
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000037069 Thromboinflammation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940125808 covalent inhibitor Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present application is directed to a new parenteral antiviral pharmaceutical composition intended for the prevention and treatment of severe acute respiratory syndrome (SARS), as well as diseases caused by SARS, including coronavirus diseases.
- SARS severe acute respiratory syndrome
- SARS diseases are caused by coronaviruses.
- the SARS viruses have a tropism for the epithelium of the mucous membranes of the respiratory system. They are characterized by catarrhal damage to the mucous membranes of the larynx, trachea, and bronchi with involvement of the lungs in the process.
- the infections are transmitted mainly by aerosol transmission.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is RNA virus that causes a 2019 Coronavirus Disease (COVID-19). SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic. SARS-CoV-2 is a virus that belongs to a type of coronavirus associated with SARS-CoV (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (April 2020). “The species Severe acute respiratory syndrome - related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nat. Microbiol. 2020, 5(4), 536-544. doi:10.1038/s41564-020-0695-z).
- SARS-CoV-2 is the successor to the SARS-CoV-1 virus that caused the SARS outbreak in 2002-2004 (“New coronavirus stable for hours on surfaces”. National Institutes of Health (NIH). NIH.gov. 17 Mar. 2020. Archived from the original on 23 Mar. 2020. Retrieved 4 May 2020). SARS-CoV-2 has undergone many changes in two years, and each new mutation has been more perfect than the previous one.
- the Delta mutation is spreading across continents at an alarming rate. Delta penetrates lung cells more easily than the original virus (the virus that circulated in the early stages of the pandemic).
- Delta strain is more effective in combining infected lung cells with uninfected ones. This could contribute to the more severe course of COVID-19. It is currently the predominant variant of SARS-CoV-2 worldwide. Delta is believed to be more than twice as infectious as previous SARS-CoV-2 variants (K. Katella. 5 Things to Know About the Delta Variant. Yale Medicine NOVEMBER 19, 2021. https://www.yalemedicine.org/nMws/5-things-to-know-delta-variant-covid).
- the new variant of coronavirus Omicron was detected in laboratories in Botswana and South Africa on 22 Nov. 2021.
- the variant has an unusually large number of mutations, several of which are novel and a significant number of which affect the spike protein targeted by most COVID-19 vaccines at the time of discovering the Omicron variant. This level of variation has led to concerns regarding its transmissibility, immune system evasion, and vaccine resistance. Omicron spreads faster than any previously known variant.
- Vaccination remains one of the main public health interventions to combat SARS-CoV-2.
- vaccine development times of at least six months limit their applicability during outbreaks of new strains of SARS-CoV-2, like the Omicron strain. Therefore, the new development of new highly effective anticoronavirus drugs is an urgent task.
- Nirmatrelvir (BEXOVID, PF-07321332, - hereinafter referred to as “NIMR”) inhibits a cysteine residue in the 3C-like protease (3CLPRO) of RNK, viruses including of SARS-CoV-2.
- Ritonavir slows down NIMR’s breakdown to help it remain in the body for a longer period at higher concentrations.
- PAX NIMR tablets and ritonavir tablets, co-packaged for oral use
- COVID-19 mild-to-moderate coronavirus disease
- PAX PAX
- COVID-19 mild-to-moderate coronavirus disease
- pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
- PAX is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
- PAX is administered as three tablets (two tablets of NIMR and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. PAX is not authorized for use for longer than five consecutive days (https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-el-primer-tratamiento-antiviral-oral).
- Previous attempts to provide an anticoronavirus drug also include a method of treating of moderate COVID-19 patients by the intravenous aprotinin (APR) and oral AVIFAVIR (favipiravir, FVP) combination therapy.
- APR intravenous aprotinin
- FVP favipiravir
- This therapy is more effective because primary and secondary efficacy endpoints of therapy by the APR + FVP combination significantly better than efficacy endpoints of therapy by the individual components (Table 1).
- drug also called medicine, medicament, pharmaceutical composition, or medicinal drug
- drug refers to a drug used to diagnose, cure, treat, or prevent disease and means a substance (or a mixture of substances in the form of a pharmaceutical composition).
- oral drug refers to solutions, powders, tablets, capsules, and pills that are taken by mouth and swallowed.
- parenteral drug refers to drugs that are injected into the body bypassing the gastrointestinal tract.
- Parenteral drugs are solutions for injection, inhalation, sprays, including for nasal or drip application, and other finished dosage forms, in this case intended for the treatment and prevention of viral infections and diseases caused by them.
- parenteral therapies are administration of drugs is primarily injections (intravenously, into the muscles, under the skin), inhalations and nasally (spray, drops).
- composition means a composition comprising at least two active ingredients (substances), namely aprotinin an inhibitor of RNA viruses, and at least one excipient.
- parenteral pharmaceutical composition is intended for parenteral administration of drugs into the body of a patient. These are primarily intravenous, inhalation and nasal routes of drug administration.
- excipient refers to a compound that is used to prepare a pharmaceutical composition and is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes excipients that are acceptable to humans and animals.
- the present application uses primarily excipients selected from the series: water, sodium chloride, L-lysine monohydrate, sodium hydroxide, hydrochloric acid, benzyl alcohol, ethanol, glycerin, dimethyl sulfoxide, peppermint oil, 1,1,1,2-tetrafluoroethane, and some others.
- combination therapy is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical. “Pharmaceutical” combination therapy may be achieved by prescribing/administering separate drugs, or, where available, dosage forms that contain more than one active ingredient (such as fixed-dose combinations).
- terapéuticaally effective amount means the amount of medicine needed to reduce the symptoms of a disease in a patient.
- the dose of medicine will be tailored to the individual requirements in each case. This dose can vary widely depending on numerous factors, such as the severity of the patient’s illness, the age and general health of the patient, other drugs with which the patient is being treated, the method and form of administration of medicine, and the experience of the attending physician.
- treatment is started with a large initial “loading dose” to rapidly reduce or eliminate the virus and followed by tapering the dose to a level sufficient to prevent an outbreak of infection.
- patient means a mammal including but not limited to humans, cattle, pigs, sheep, chickens, turkeys, buffaloes, llamas, ostriches, dogs, cats, hamsters, and mice, preferably the patient is a human.
- active ingredient means aprotinin and an inhibitor of RNA viruses used in a pharmaceutical composition or drug.
- the first aspect of the present application relates to pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, using aprotinin (APR), ritonavir and/or Nirmatrelvir (BEXOVID, PF-07321332, -hereinafter referred to as “NIMR”) and excipients.
- APR aprotinin
- ritonavir and/or Nirmatrelvir
- BEXOVID Nirmatrelvir
- PF-07321332 PF-07321332, -hereinafter referred to as “NIMR”
- Another aspect of the present application is a pharmaceutical kit for a pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, consisting of: the parenteral drug TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, or others parenteral drugs including APR, or aqueous or saline solution containing APR and a drug including ritonavir or aqueous or saline solution containing ritonavir, or its lyophilizate and / or a drug BEXOVID or aqueous or saline solution containing Nirmatrelvir or its lyophilizate.
- Another aspect of the present application is a pharmaceutical composition in the form of an aqueous solution (APC) or lyophilizate (PCL) for a pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, including APR, ritanovir and/or NIMR and excipients.
- APC aqueous solution
- PCL lyophilizate
- a preferred anti-SARS-CoV-2 / COVID-19 viral pharmaceutical composition is in form of a lyophilizate (PCL) containing APR, NIMR and excipients.
- PCL lyophilizate
- excipients are selected from the series: water, sodium chloride, L-lysine monohydrate, sodium hydroxide, hydrochloric acid, benzyl alcohol, ethanol, glycerin, dimethyl sulfoxide, peppermint oil, 1,1,1,2-tetrafluoroethane, and others.
- APR is a drug with a long history of clinical use since the 1960s and a good safety profile.
- APR under the trade names TRASYLOL®, ANTAGOSAN®, CONTRYCAL®, GORDOX®, and others, is used as an intravenous medication given by injection to reduce bleeding during complex surgeries such as heart and liver surgery (https://www.rxlist.com/trasylol-drug.htm#indications; https://yandex.ru/health/pills/product/gordoks-203), as an antiviral drug for the treatment and prevention of viral respiratory diseases (US 5723439).
- APR is a nonspecific inhibitor of the serine proteases - especially trypsin, chymotrypsin, plasmin, and kallikrein.
- the inhibition of kallikrein leads to inhibition of factor XIIa formation, inhibition of the intrinsic pathway of coagulation, fibrinolysis, and thrombin generation, and to the attenuation of the pro-inflammatory response (Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med. Drug. Discov. 2020, 100052; doi: 10.1016/j.medidd.2020.100052).
- APR by inhibiting kallikreins, regulates coagulation by affecting factor XII, plasminogen, and PAR-1 thrombin receptor.
- SARS CoV-2 promotes thrombo-inflammation involves activation of the kallikreins that trigger neutrophilia by the viral capsid proteins, which leads to the formation of neutrophil extracellular networks (NETs) and vascular microthrombus formation (Colling M. E., Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc. Med. 2020, 25(5), 471-478. doi:10.1177/1358863X20932640).
- aprotinin as a nonspecific protease inhibitor, can exert such a multi-tiered anti-inflammatory mechanism of action. Its activity ranges from reduced contact activation of platelets and leukocytes, to reduced extravasation and degranulation of leukocytes, reduced systemic cytokine production, reduced endothelial cell activation, reduced vascular permeability, and reduced bronchial epithelial cell activation (Landis R. C. et al. The antithrombotic and anti-inflammatory mechanisms of action of aprotinin. Ann. Thorac. Surg. 2001, 72 (6), 2169-2175. doi: 10.1016/S0003-4975(01)02821-1. ) .
- APR inhibits the entry of SARS-CoV-2 into cells ((a) M. Hoffmann et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181 (2), 271-280. e8. doi: 10.1016/j.cell.2020.02.052; (b) D. Bojkova et al. Aprotinin Inhibitors SARS-CoV-2 Replication. Cells 2020, 9 (11), 2377. https: //doi.org/10.3390/cells9112377) and can be used for the prevention and treatment of SARS-CoV-2/COVID-19 (RU 2738885).
- NIMR Neuronal peptidomimetic developed by Pfizer which acts as an orally active 3C-like protease inhibitor of a cysteine residue in the 3C-like protease (3CLPRO) of RNK, viruses including of SARS-CoV-2.
- NIMR is a covalent inhibitor, binding directly to the catalytic cysteine (Cys145) residue of the cysteine protease enzyme (Pavan M. et al. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J. Enzyme Inhib. Med. Chem. 2021, 36 (1), 1646-1650. doi:10.1080/14756366.2021.1954919).
- the inventors of the present application unexpectedly found that the active ingredients (APR and NIMR) included in the new anti-SARS-CoV-2/COVID-19 pharmaceutical composition do not interact with each other during the preparation, short-term storage, and this composition can use as a parenteral drug.
- Another aspect of the present application is directed to anti-SARS-CoV-2/COVID-19 viral parenteral drug, which is PPC of certain embodiments of the present application.
- the parenteral drug and PPC according to the present application is intended for the prevention and treatment mainly of SARS-CoV-2 and COVID-19.
- Another aspect of the present application is directed to the containing a PPC of the present application container.
- Another aspect of the present application is directed to an ampoule and a bottle containing an APC of the present application.
- Another aspect of the present application is directed to an inhaler (nebulizer) selected from a number of compressor or ultrasonic or electronic mesh inhaler (nebulizer) containing the APC of the present application.
- nebulizer selected from a number of compressor or ultrasonic or electronic mesh inhaler (nebulizer) containing the APC of the present application.
- Another aspect of the present application is directed to a pocket or portable inhaler (nebulizer) containing the APC of the present application.
- Another aspect of the present application is directed to a container, which is a can for nasal spray containing the APC of the present application.
- Another aspect of the present application is directed to a method for the prevention and/or treatment of SARS-CoV-2 infection and/or disease associated with this infection in a patient by a parenteral (intravenous, inhalation, or intranasal) administration to the patient of the APC of the present application in a therapeutically effective amount.
- a parenteral intravenous, inhalation, or intranasal
- patients are treated by intravenous administration of with the parenteral drug or the APC of the present application in a therapeutically effective amount once or twice a day (as prescribed by a physician, depending on the patient’s condition).
- prophylaxis of patients is carried out with a therapeutically effective amount of a nasal spray, which is the APC of the present application.
- the prophylaxis is carried out using balloons for nasal spray into the nose (into the nasopharynx) and throat 3-6 times a day into each nostril and the throat (about 1 ml per session and about 3-6 ml per day).
- the prophylaxis and treatment of patients is carried out by inhalation using ultrasonic nebulizers 3-6 times a day for 5-7 days a therapeutically effective amount of APC according to the present application.
- Another aspect of the present application is directed to the use of the APC or the parenteral drug of the present application for the prevention and/or treatment of the RNA viral infection (SARS-CoV-2) and/or disease associated with this infection (COVID-19) by intravenous, or inhalation, or intranasal administration to a patient of the APC or the parenteral drug of the present application in a therapeutically effective amount.
- SARS-CoV-2 RNA viral infection
- COVID-19 chronic RNA viral infection
- Another aspect of the present application is directed to the use of the APC or the parenteral drug of the present application in a therapeutically effective amount for the prevention and/or treatment of the RNA viral infection (SARS-CoV-2) and/or disease associated with this infection (COVID-19).
- SARS-CoV-2 RNA viral infection
- COVID-19 disease associated with this infection
- the use of the new APC and the new parenteral drug of the present application provides, thanks to their inhibitor of replication (NIMR) of SARS-CoV-2 in the cell and inhibitor of entry (APR) of SARS-CoV-2 into the cell, have increased anti-SARS-CoV-2 activity.
- NIMR inhibitor of replication
- APR inhibitor of entry
- the use of the new APC and the new parenteral drug of the present application provides, thanks to APR, a reduction in inflammation and thrombus formation in the moderate and severe COVID-19 patients.
- Another aspect of the present application is directed to a method of obtaining the APC or the parenteral drug of the present application by dissolving NIMR, APR and excipients in saline (0.9% aqueous sodium chloride solution).
- Another aspect of the present application is directed to a method of obtaining the APC or the new parenteral drug of the present application by dissolving a lyophilizate containing NIMR, APR and excipients in saline.
- the active ingredients and the APC of the present application retain their activity in a convenient lyophilized form for storage.
- APR in the form of a powder or a lyophilizate, or a concentrate, or a drug selected from the group consisting of TRASYLOL®, GORDOX®, APROTEX®, and TRASKOLAN® for preparing the APC or the parenteral drug of the present application.
- Another aspect of the present application is directed to the use of NIMR in the form of a powder, or a lyophilizate, or a concentrate for preparing the PPC or the parenteral drug of the present application.
- NIMR intracranial magnetic resonance
- Another aspect of the present application is a method for preparing the anti-SARS-CoV-2/COVID-19 pharmaceutical composition in form of PCL by dissolving APR, NIMR in the form of a powder, or a lyophilizate, or the water solution, and excipients in water or saline followed by lyophilization of the resulting mixture.
- Another aspect of the present application is a method for preparing the PCL by dissolving NIMR in the form of a powder, or a lyophilizate, or the water solution, and excipients in TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, followed by lyophilization of the resulting mixture.
- the PPC can be obtained, including immediately before use, by sequential dissolution in physiological solution of the crystalline APR or its lyophilizate, the crystalline NIMR or its lyophilizate and, if necessary, excipients.
- the APS can be obtained, including immediately before use, by dissolving the crystalline NIMR or its lyophilizate in an aqueous solution of APR or in known drugs that are aqueous solutions of APR, for example, Trasylol®, Gordox®, Aprotex®, or Traskolan®, and, if necessary, bringing the resulting compositions to the required concentration of active ingredients with saline.
- the APC can be obtained, including immediately before use, by dissolution of BEXOVID in an aqueous solution of APR.
- the APC can be obtained, including immediately before use, by dissolution of BEXOVID in the known drugs that are aqueous solutions of APR, for example, TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, and, if necessary, bringing the resulting compositions to the required concentration of active ingredients with saline.
- APR for example, TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, and, if necessary, bringing the resulting compositions to the required concentration of active ingredients with saline.
- the new PPC can be obtained, including immediately before use, by sequential dissolution in saline of crystalline APR or its lyophilizate, for example, Contrykal®, the crystalline NIMR or its lyophilizate and, if necessary, excipients.
- mice B6.Cg-Tg(K18-ACE2)2Prlmn/HEMI Hemizygous for Tg(K18-CE2)2Prlmn from Jackson Immuno-research, West Grove, PA, USA; females, age - 6-8 weeks, weighing 19-24 g
- SARS-CoV-2 (“Dubrovka” strain, identification number GenBank: MW161041.1)
- a statistically significant reduction in virus titer by 4.2-4.6 orders of magnitude was obtained in the lungs of infected animals, compared with the control group of infected but untreated animals.
- anti-RNA viral preparation anti-RNA viral pharmaceutical composition
- Example 1 Preparation of the anti-SARS-CoV-2/COVID-19 pharmaceutical composition (APC-1 - APC-3, PCL-2).
- APC-1 NIMR from Shanghai XingMo Biotechnology Co., Ltd., China (20.0 mg), and APR from Wanhua Biochem, China (37.0 mg, 200,000 KIU), with an activity of 5400 KIU mg were dissolved in saline (20 ml) under ultrasonic stirring for 5 minutes to yield 20 ml APC-1 containing NIMR (1.0 mg/ml) and APR (10,000) KIU/ml.
- APC-2 and PCL-2 200.0 mg of NIMR from Shanghai XingMo Biotechnology Co., Ltd., China were dissolved in 10 ml GORDOX under ultrasonic stirring for 5 minutes to yield 10 ml APC-2 containing 20.0 mg/ml of NIMR and 10,000 KIU/ml of APR. The resulting APC-2 was lyophilized to give PCL-2 containing 200 mg NIMR and 100,000 KIU APR.
- APC-3 100.0 mg of NIMR from Shanghai XingMo Biotechnology Co., Ltd., China were dissolved in 10 ml GORDOX + 90 ml saline under ultrasonic stirring for 5 minutes to yield 100 ml APC-3 containing 1.0 mg/ml of NIMR and 1,000 KIU/ml of APR.
- Example 2 Stability of APC-1.
- the stability of APC-1 was studied by UV spectroscopy on an Agilent 8453 spectrophotometer after storage under normal conditions (1) and under stress tests (after exposure for 24 hours in the light at 25° C. (2); after exposure for 48 hours in the dark at 3-5° C. (3); after exposure for 48 hours in the dark at 25° C. (4); and after exposure for 48 hours in the dark at 60° C. (5)).
- the optical densities of the maxima of the initial spectra (condition 1) APC-1 differ greatly from those in the stress test.
- the percentage of change in optical density under conditions 3-5 compared to optical density under Conditions 1 is > 2%. This indicates that APC-1 and APC-2 from are limitedly stable under rapid tests conditions and them must be used within a few hours after preparation.
- Example 3 A device for inhalation therapy and prevention of SARS-CoV-2 / COVID-19. 5 - 10 ml of APC-3 containing NIMR (1 mg/ml) and APR (1,000 KIU/ml) is placed into a compression nebulizer Omron NE-C300 Complete or in a portable ultrasonic Feellife Aerogo mesh nebulizer and is receive the device for inhalation therapy and prevention of SARS-CoV-2 / COVID-19.
- Example 4 Devices for nasal spray therapy and prevention of SARS-CoV-2 / COVID-19. 5 - 10 ml of APC 3 containing NIMR (1 mg/ml) and APR (1000 KIU/ml) is placed into a plastic can for nasal and is receive the device for nasal therapy and prevention of SARS-CoV-2 / COVID-19.
- Example 5 Treatment with APC-2 of transgenic mice infected with mouse-adapted SARS-CoV-2.
- mice B6.Cg-Tg(K18-ACE2)2Prlmn/HEMI Hemizygous for Tg(K18-CE2)2Prlmn from Jackson Immuno-research, West Grove, PA, USA
- females age - 6-8 weeks, weighing 19-24 g, were formed, 4 animals per group.
- mice on day 1 in the morning the mice were infected with SARS-CoV-2, and then 5 ml/kg of water for injection was intragastrical administered immediately after infection and in the evening of the same day.
- Treatment regimen for transgenic mice parenteral (intraperitoneal) administration of drugs 2 times a day; day 0 - 1 hour before infected with mouse-adapted SARS-CoV-2 (“Dubrovka” strain, identification number GenBank: MW161041.1) and 6-8 hours after infection; days 1, 2, 3 - 2 times a day, for a total of 4 days (days 0, 1, 2, 3); Day 4 - lung sampling from all animals to assess the virus titer in the lungs, visual assessment of the lungs and transfer of the lungs for histology; days 0 -4 - daily assessment of body weight and condition of mice.
- mice from all groups were infected with the SARS-CoV-2 “Dubrovka” virus (10 3.5 TCID 50 /ml). All mice were infected intranasally under light ether anesthesia in a volume of 30 ⁇ l for both nostrils.
- Euthanasia Painless killing of the animal was carried out by the responsible person in accordance with the existing ethical requirements, by dislocation of the cervical vertebrae with preliminary anesthesia with ether. Euthanasia was performed promptly after the end of the experiments.
- the animals in each group were sacrificed and the lungs were removed under sterile conditions.
- One lung was fixed in formalin for further histology, the second lung was prepared to measure the virus titer.
- the lungs were homogenized and resuspended in 1 ml of cold sterile PBS.
- the suspension was cleared from cell debris by centrifugation at 2000 g for 10 min, and the supernatant was used to determine the infectious titer of the virus in cell culture and to perform PCR.
- the obtained samples were stored at -80° C. until the experiments were carried out.
- Vero CCL81 cells were seeded in 96-well Costar plates with an average density of 20,000 cells per well and grown in DMEM medium in the presence of 5% fetal calf serum, 10 mM glutamine and antibiotics (penicillin 100 IU/well). ml and streptomycin 100 ⁇ g/ml) until a complete monolayer is formed (within 3 days). Before infection with the virus, the cell culture was washed twice with DMEM medium without serum. 10-fold dilutions of each lung virus sample were prepared from 10-1 to 10-7.
- the prepared dilutions in a volume of 200 ⁇ L were added to cell culture plates and incubated in 5% CO2 at 37° C. for 5 days until a cytopathic effect (CPE) appeared in virus control cells. Accounting for the result of the manifestation of CPP in cells was carried out using a quantitative MTT test.
- the virus titer was calculated using the Ramakrishnan M.A formula in the Excel program [M.A. Ramakrishnan. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016, 5, 85-86.
- TID 50 The median tissue culture infectious dose is defined as the dilution of a virus required to infect 50% of a given cell culture.) [I. Leneva et al. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses 2021, 13(8): 1665. doi: 10.3390/v13081665]. Next, the average titer value for samples from mice of the same group was calculated.
- the effectiveness of the drugs in a model of the transgenic mice infected with mouse-adapted SARS-CoV-2 was assessed according to decrease in the titer of the virus in the lungs of animals after 4 days.
- parenteral (intraperitoneal) treatment of mice infected with SARS-CoV-2 resulted in a reduction in virus titer in the lungs of infected animals compared to a control group of infected but untreated animals.
- parenteral monotherapy with APR or NIMR a decrease in virus titer (logTCID 50 /ml) by 1.52 and 2.35, respectively, was observed.
- combination parenteral therapy of APR + MOV provides a decrease in virus titer by 3.2 orders of magnitude.
- Example 6 Intravenous treatment of Syrian hamsters infected with the SARS-CoV-2 using the APC-2 containing NIMR and APR.
- the efficacy of the APC-2 of the present application was evaluated using a model of SARS-CoV-2 infection in Syrian hamsters [R. Boudewijns et al. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters. BioRxiv preprint. doi: https://doi.org/10.1101/2020.04.23.056838; this version posted Apr. 24, 2020. https://www.biorxiv.org/content/10.1101/2020.04.23.056838v1].
- the strain SARS-CoV-2 hCoV-19/Australia/VIC01/2020 was obtained from the State Research Center of Virology and Biotechnology VECTOR ( Russia).
- the infectious virus was isolated by sequential passage in Vero E6 cells.
- the titer of the viral suspension was determined by endpoint dilution on Vero E6 cells using the Reed-Muench method.
- the work related to the live virus was carried out under isolated laboratory conditions that meet the international BSL-3 + VECTOR requirements.
- Vero E6 cells from VECTOR Collection of Cell Cultures were cultured in Minimum Essential Medium (MEM) (Gibco) supplemented with 10% fetal bovine serum (Integro), 1% L-glutamine (Gibco), and 1% Bicarbonate (Gibco). Endpoint titrations were performed with a medium containing 2% fetal bovine serum.
- Group 1 - control group untreated hamsters. Dose: 5 ml/kg saline.
- the drugs were injected under light isoflurane anesthesia intravenously, 2 times a day for 4 days, starting the first injection one hour before infection, 6 hours after infection, then for 3 days after 12 hours.
- Real-time PCR was performed on the LightCycler96 platform (Roche) using the iTaq Universal Probes One-Step RT-qPCR kit (BioRad) [R.
- lung tissue was fixed in 4% formaldehyde, embedded in paraffin, and stained with hematoxylin-eosin. Damage was assessed on a scale from 1 to 3: stagnation, intra-alveolar bleeding, apoptotic bodies in the bronchial epithelium, necrotic bronchiolitis, perivascular edema, bronchopneumonia, perivascular inflammation, peribronchial inflammation, and vascular inflammation.
- APC-2 comprising NIMR and APR demonstrated a high anti-SARS-CoV-2/COVID-19 efficacy.
- the titer of SARS CoV-2 in the tissues of the lungs decreased by more than an order of magnitude compared to the control group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application is a Continuation of U.S. Application No. 17/709,727, filed Mar. 31, 2022, the entire contents of which are incorporated herein by reference in their entirety.
- The present application is directed to a new parenteral antiviral pharmaceutical composition intended for the prevention and treatment of severe acute respiratory syndrome (SARS), as well as diseases caused by SARS, including coronavirus diseases.
- SARS diseases (e.g., COVID-19) are caused by coronaviruses. The SARS viruses have a tropism for the epithelium of the mucous membranes of the respiratory system. They are characterized by catarrhal damage to the mucous membranes of the larynx, trachea, and bronchi with involvement of the lungs in the process. The infections are transmitted mainly by aerosol transmission.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is RNA virus that causes a 2019 Coronavirus Disease (COVID-19). SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic. SARS-CoV-2 is a virus that belongs to a type of coronavirus associated with SARS-CoV (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (April 2020). “The species Severe acute respiratory syndrome - related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nat. Microbiol. 2020, 5(4), 536-544. doi:10.1038/s41564-020-0695-z). This virus was first identified in December 2019 in Wuhan city, Hubei province, China. On Mar. 11, 2020, WHO declared the outbreak a public health emergency of international concern. SARS-CoV-2 is the successor to the SARS-CoV-1 virus that caused the SARS outbreak in 2002-2004 (“New coronavirus stable for hours on surfaces”. National Institutes of Health (NIH). NIH.gov. 17 Mar. 2020. Archived from the original on 23 Mar. 2020. Retrieved 4 May 2020). SARS-CoV-2 has undergone many changes in two years, and each new mutation has been more perfect than the previous one. First discovered in India in December 2020, the Delta mutation is spreading across continents at an alarming rate. Delta penetrates lung cells more easily than the original virus (the virus that circulated in the early stages of the pandemic). In addition, the Delta strain is more effective in combining infected lung cells with uninfected ones. This could contribute to the more severe course of COVID-19. It is currently the predominant variant of SARS-CoV-2 worldwide. Delta is believed to be more than twice as infectious as previous SARS-CoV-2 variants (K. Katella. 5 Things to Know About the Delta Variant. Yale Medicine NOVEMBER 19, 2021. https://www.yalemedicine.org/nMws/5-things-to-know-delta-variant-covid).
- The new variant of coronavirus Omicron was detected in laboratories in Botswana and South Africa on 22 Nov. 2021. The variant has an unusually large number of mutations, several of which are novel and a significant number of which affect the spike protein targeted by most COVID-19 vaccines at the time of discovering the Omicron variant. This level of variation has led to concerns regarding its transmissibility, immune system evasion, and vaccine resistance. Omicron spreads faster than any previously known variant.
- As of Dec. 17, 2021, 77 countries have now reported cases of Omicron, and “the reality is that Omicron is probably in most countries, even if it hasn’t been detected yet (L. Smith-Spark, What can the world learn from countries where Omicron is surging? CNN Fri Dec. 17, 2021. https://www.cnn.com/2021/12/17/health/covid-omicron-what-can-the-world-learn-cmd-intl/index.html).
- As of Jan. 28, 2022, 364,191,494 confirmed cases of people infected with coronavirus were registered in the world, of which 5,631,457 unfortunately died (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).
- Vaccination remains one of the main public health interventions to combat SARS-CoV-2. However, vaccine development times of at least six months limit their applicability during outbreaks of new strains of SARS-CoV-2, like the Omicron strain. Therefore, the new development of new highly effective anticoronavirus drugs is an urgent task.
- Previous attempts to provide an anticoronavirus drug include a nirmatrelvir/ritonavir combination sold under the brand name PAXLOVID (PAX). Nirmatrelvir (BEXOVID, PF-07321332, - hereinafter referred to as “NIMR”) inhibits a cysteine residue in the 3C-like protease (3CLPRO) of RNK, viruses including of SARS-CoV-2. Ritonavir slows down NIMR’s breakdown to help it remain in the body for a longer period at higher concentrations.
- On Dec. 22, 2021, the United States FDA issued an emergency use authorization (EUA) for Pfizer’s PAX (NIMR tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. PAX is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. PAX is administered as three tablets (two tablets of NIMR and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. PAX is not authorized for use for longer than five consecutive days (https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-el-primer-tratamiento-antiviral-oral).
- Previous attempts to provide an anticoronavirus drug also include a method of treating of moderate COVID-19 patients by the intravenous aprotinin (APR) and oral AVIFAVIR (favipiravir, FVP) combination therapy. This therapy is more effective because primary and secondary efficacy endpoints of therapy by the APR + FVP combination significantly better than efficacy endpoints of therapy by the individual components (Table 1). (Ivashchenko A. A. et al. Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients. Viruses 2021, 13, 1253. https://doi.org/10.3390/v13071253.).
-
TABLE 1 Primary and secondary efficacy endpoints of therapy by the intravenous aprotinin (APR), oral AVIFAVIR (favipiravir, FVP) and their combination. Primary and Secondary Efficacy Endpoints APR + SOC FVP + SOC) APR + FVP + SOC Median time to elimination of SARS-CoV-2 confirmed by RT-PCR, days (IQR) 7.5 (6-9) 4.5 (4-9) 3.5 (3-4) Median time to normalization of CRP concentration (≤10 mg/L) in patient’s blood, days (IQR) 6.0 (6-6) 14.0 (5.5-14) 3.5 (3-5) Median time to normalization of D-dimer concentration (<253 ng/mL) in patient’s blood, days (IQR) 4.5 (3-6) NA 5.0 (4-5) Median time to normalization of body temperature (<37° C.), days (IQR) 3.0 (2-3) 2.0 (1-3) 1.0 (1-3) Median time to improvement in clinical status by 2 points on the WHO-OSCI, days (IQR) 11.0 (6-11) 14.0 (11.5-16) 5.0 (5-5) - The term “drug” (also called medicine, medicament, pharmaceutical composition, or medicinal drug) refers to a drug used to diagnose, cure, treat, or prevent disease and means a substance (or a mixture of substances in the form of a pharmaceutical composition).
- The term “oral drug” refers to solutions, powders, tablets, capsules, and pills that are taken by mouth and swallowed.
- The term “parenteral drug” refers to drugs that are injected into the body bypassing the gastrointestinal tract. Parenteral drugs are solutions for injection, inhalation, sprays, including for nasal or drip application, and other finished dosage forms, in this case intended for the treatment and prevention of viral infections and diseases caused by them.
- The term “parenteral therapies” are administration of drugs is primarily injections (intravenously, into the muscles, under the skin), inhalations and nasally (spray, drops).
- The term “pharmaceutical composition” as used herein means a composition comprising at least two active ingredients (substances), namely aprotinin an inhibitor of RNA viruses, and at least one excipient.
- The term “parenteral pharmaceutical composition (PPC)” is intended for parenteral administration of drugs into the body of a patient. These are primarily intravenous, inhalation and nasal routes of drug administration.
- The term “excipient” as used herein refers to a compound that is used to prepare a pharmaceutical composition and is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes excipients that are acceptable to humans and animals. The present application uses primarily excipients selected from the series: water, sodium chloride, L-lysine monohydrate, sodium hydroxide, hydrochloric acid, benzyl alcohol, ethanol, glycerin, dimethyl sulfoxide, peppermint oil, 1,1,1,2-tetrafluoroethane, and some others.
- The term “combination therapy” is therapy that uses more than one medication or modality. Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical. “Pharmaceutical” combination therapy may be achieved by prescribing/administering separate drugs, or, where available, dosage forms that contain more than one active ingredient (such as fixed-dose combinations).
- The term “therapeutically effective amount” or “dose” as used herein means the amount of medicine needed to reduce the symptoms of a disease in a patient. The dose of medicine will be tailored to the individual requirements in each case. This dose can vary widely depending on numerous factors, such as the severity of the patient’s illness, the age and general health of the patient, other drugs with which the patient is being treated, the method and form of administration of medicine, and the experience of the attending physician. Typically, treatment is started with a large initial “loading dose” to rapidly reduce or eliminate the virus and followed by tapering the dose to a level sufficient to prevent an outbreak of infection.
- The term “patient” means a mammal including but not limited to humans, cattle, pigs, sheep, chickens, turkeys, buffaloes, llamas, ostriches, dogs, cats, hamsters, and mice, preferably the patient is a human.
- The term “active ingredient (substance)” as used herein means aprotinin and an inhibitor of RNA viruses used in a pharmaceutical composition or drug.
- The first aspect of the present application relates to pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, using aprotinin (APR), ritonavir and/or Nirmatrelvir (BEXOVID, PF-07321332, -hereinafter referred to as “NIMR”) and excipients.
- Another aspect of the present application is a pharmaceutical kit for a pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, consisting of: the parenteral drug TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, or others parenteral drugs including APR, or aqueous or saline solution containing APR and a drug including ritonavir or aqueous or saline solution containing ritonavir, or its lyophilizate and / or a drug BEXOVID or aqueous or saline solution containing Nirmatrelvir or its lyophilizate.
- Another aspect of the present application is a pharmaceutical composition in the form of an aqueous solution (APC) or lyophilizate (PCL) for a pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19, including APR, ritanovir and/or NIMR and excipients.
- According to the present application, a preferred anti-SARS-CoV-2 / COVID-19 viral pharmaceutical composition is in form of a lyophilizate (PCL) containing APR, NIMR and excipients.
- The excipients are selected from the series: water, sodium chloride, L-lysine monohydrate, sodium hydroxide, hydrochloric acid, benzyl alcohol, ethanol, glycerin, dimethyl sulfoxide, peppermint oil, 1,1,1,2-tetrafluoroethane, and others.
- APR is a drug with a long history of clinical use since the 1960s and a good safety profile. APR, under the trade names TRASYLOL®, ANTAGOSAN®, CONTRYCAL®, GORDOX®, and others, is used as an intravenous medication given by injection to reduce bleeding during complex surgeries such as heart and liver surgery (https://www.rxlist.com/trasylol-drug.htm#indications; https://yandex.ru/health/pills/product/gordoks-203), as an antiviral drug for the treatment and prevention of viral respiratory diseases (US 5723439).
- APR is a nonspecific inhibitor of the serine proteases - especially trypsin, chymotrypsin, plasmin, and kallikrein. The inhibition of kallikrein leads to inhibition of factor XIIa formation, inhibition of the intrinsic pathway of coagulation, fibrinolysis, and thrombin generation, and to the attenuation of the pro-inflammatory response (Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med. Drug. Discov. 2020, 100052; doi: 10.1016/j.medidd.2020.100052).
- APR by inhibiting kallikreins, regulates coagulation by affecting factor XII, plasminogen, and PAR-1 thrombin receptor. The mechanism by which SARS CoV-2 promotes thrombo-inflammation involves activation of the kallikreins that trigger neutrophilia by the viral capsid proteins, which leads to the formation of neutrophil extracellular networks (NETs) and vascular microthrombus formation (Colling M. E., Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc. Med. 2020, 25(5), 471-478. doi:10.1177/1358863X20932640).
- The distribution of serine proteases throughout the vasculature and the key role they play in inflammation may explain how aprotinin, as a nonspecific protease inhibitor, can exert such a multi-tiered anti-inflammatory mechanism of action. Its activity ranges from reduced contact activation of platelets and leukocytes, to reduced extravasation and degranulation of leukocytes, reduced systemic cytokine production, reduced endothelial cell activation, reduced vascular permeability, and reduced bronchial epithelial cell activation (Landis R. C. et al. The antithrombotic and anti-inflammatory mechanisms of action of aprotinin. Ann. Thorac. Surg. 2001, 72 (6), 2169-2175. doi: 10.1016/S0003-4975(01)02821-1.).
- APR inhibits the entry of SARS-CoV-2 into cells ((a) M. Hoffmann et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181 (2), 271-280. e8. doi: 10.1016/j.cell.2020.02.052; (b) D. Bojkova et al. Aprotinin Inhibitors SARS-CoV-2 Replication. Cells 2020, 9 (11), 2377. https: //doi.org/10.3390/cells9112377) and can be used for the prevention and treatment of SARS-CoV-2/COVID-19 (RU 2738885).
- NIMR (Nirmatrelvir, BEXOVID, PF-07321332) is an antiviral peptidomimetic developed by Pfizer which acts as an orally active 3C-like protease inhibitor of a cysteine residue in the 3C-like protease (3CLPRO) of RNK, viruses including of SARS-CoV-2. NIMR is a covalent inhibitor, binding directly to the catalytic cysteine (Cys145) residue of the cysteine protease enzyme (Pavan M. et al. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J. Enzyme Inhib. Med. Chem. 2021, 36 (1), 1646-1650. doi:10.1080/14756366.2021.1954919).
- The inventors of the present application unexpectedly found that the active ingredients (APR and NIMR) included in the new anti-SARS-CoV-2/COVID-19 pharmaceutical composition do not interact with each other during the preparation, short-term storage, and this composition can use as a parenteral drug.
- Another aspect of the present application is directed to anti-SARS-CoV-2/COVID-19 viral parenteral drug, which is PPC of certain embodiments of the present application.
- The parenteral drug and PPC according to the present application is intended for the prevention and treatment mainly of SARS-CoV-2 and COVID-19.
- Another aspect of the present application is directed to the containing a PPC of the present application container.
- Another aspect of the present application is directed to an ampoule and a bottle containing an APC of the present application.
- Another aspect of the present application is directed to an inhaler (nebulizer) selected from a number of compressor or ultrasonic or electronic mesh inhaler (nebulizer) containing the APC of the present application.
- Another aspect of the present application is directed to a pocket or portable inhaler (nebulizer) containing the APC of the present application.
- Another aspect of the present application is directed to a container, which is a can for nasal spray containing the APC of the present application.
- Another aspect of the present application is directed to a method for the prevention and/or treatment of SARS-CoV-2 infection and/or disease associated with this infection in a patient by a parenteral (intravenous, inhalation, or intranasal) administration to the patient of the APC of the present application in a therapeutically effective amount.
- In accordance with the present application, patients are treated by intravenous administration of with the parenteral drug or the APC of the present application in a therapeutically effective amount once or twice a day (as prescribed by a physician, depending on the patient’s condition).
- In accordance with the present application, prophylaxis of patients is carried out with a therapeutically effective amount of a nasal spray, which is the APC of the present application.
- In accordance with the present application, the prophylaxis is carried out using balloons for nasal spray into the nose (into the nasopharynx) and throat 3-6 times a day into each nostril and the throat (about 1 ml per session and about 3-6 ml per day).
- In accordance with the present application, the prophylaxis and treatment of patients is carried out by inhalation using ultrasonic nebulizers 3-6 times a day for 5-7 days a therapeutically effective amount of APC according to the present application.
- Another aspect of the present application is directed to the use of the APC or the parenteral drug of the present application for the prevention and/or treatment of the RNA viral infection (SARS-CoV-2) and/or disease associated with this infection (COVID-19) by intravenous, or inhalation, or intranasal administration to a patient of the APC or the parenteral drug of the present application in a therapeutically effective amount.
- Another aspect of the present application is directed to the use of the APC or the parenteral drug of the present application in a therapeutically effective amount for the prevention and/or treatment of the RNA viral infection (SARS-CoV-2) and/or disease associated with this infection (COVID-19).
- The use of the new APC and the new parenteral drug of the present application containing two active ingredients (NIMR and APR) significantly simplifies the process of prevention and treatment of patients compared with separate combination therapy by the oral drug + the parenteral drug.
- In addition, the use of the new APC and the new parenteral drug of the present application provides, thanks to their inhibitor of replication (NIMR) of SARS-CoV-2 in the cell and inhibitor of entry (APR) of SARS-CoV-2 into the cell, have increased anti-SARS-CoV-2 activity.
- In addition, the use of the new APC and the new parenteral drug of the present application provides, thanks to APR, a reduction in inflammation and thrombus formation in the moderate and severe COVID-19 patients.
- Another aspect of the present application is directed to a method of obtaining the APC or the parenteral drug of the present application by dissolving NIMR, APR and excipients in saline (0.9% aqueous sodium chloride solution).
- Another aspect of the present application is directed to a method of obtaining the APC or the new parenteral drug of the present application by dissolving a lyophilizate containing NIMR, APR and excipients in saline.
- The active ingredients and the APC of the present application retain their activity in a convenient lyophilized form for storage.
- Another aspect of the present application is directed to the use of APR in the form of a powder or a lyophilizate, or a concentrate, or a drug selected from the group consisting of TRASYLOL®, GORDOX®, APROTEX®, and TRASKOLAN® for preparing the APC or the parenteral drug of the present application.
- Another aspect of the present application is directed to the use of NIMR in the form of a powder, or a lyophilizate, or a concentrate for preparing the PPC or the parenteral drug of the present application.
- Another aspect of the present application is directed to the use of NIMR in the form of a powder, or a lyophilizate, or a concentrate and APR as TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, for preparing the PPC or the parenteral drug of the present application.
- Another aspect of the present application is a method for preparing the anti-SARS-CoV-2/COVID-19 pharmaceutical composition in form of PCL by dissolving APR, NIMR in the form of a powder, or a lyophilizate, or the water solution, and excipients in water or saline followed by lyophilization of the resulting mixture.
- Another aspect of the present application is a method for preparing the PCL by dissolving NIMR in the form of a powder, or a lyophilizate, or the water solution, and excipients in TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, followed by lyophilization of the resulting mixture.
- The PPC can be obtained, including immediately before use, by sequential dissolution in physiological solution of the crystalline APR or its lyophilizate, the crystalline NIMR or its lyophilizate and, if necessary, excipients.
- The APS can be obtained, including immediately before use, by dissolving the crystalline NIMR or its lyophilizate in an aqueous solution of APR or in known drugs that are aqueous solutions of APR, for example, Trasylol®, Gordox®, Aprotex®, or Traskolan®, and, if necessary, bringing the resulting compositions to the required concentration of active ingredients with saline.
- The APC can be obtained, including immediately before use, by dissolution of BEXOVID in an aqueous solution of APR.
- The APC can be obtained, including immediately before use, by dissolution of BEXOVID in the known drugs that are aqueous solutions of APR, for example, TRASYLOL®, or GORDOX®, or APROTEX®, or ANTAGOSAN®, or CONTRYCAL®, or TRASKOLAN®, and others, and, if necessary, bringing the resulting compositions to the required concentration of active ingredients with saline.
- The new PPC can be obtained, including immediately before use, by sequential dissolution in saline of crystalline APR or its lyophilizate, for example, Contrykal®, the crystalline NIMR or its lyophilizate and, if necessary, excipients.
- During intraperitoneal treating the transgenic mice (B6.Cg-Tg(K18-ACE2)2Prlmn/HEMI Hemizygous for Tg(K18-CE2)2Prlmn from Jackson Immuno-research, West Grove, PA, USA; females, age - 6-8 weeks, weighing 19-24 g) infected with mouse-adapted SARS-CoV-2 (“Dubrovka” strain, identification number GenBank: MW161041.1) a statistically significant reduction in virus titer by 4.2-4.6 orders of magnitude was obtained in the lungs of infected animals, compared with the control group of infected but untreated animals.
- During intravenous treating the Syrian hamsters weighing 100-120 g (State Scientific Center for Virology and Biotechnology “Vector” of Rospotrebnadzor, Russia) infected with SARS-CoV-2 (strain hCoV-19/Australia/VIC01/2020), a statistically significant reduction in virus titer by order of magnitude was obtained in the lungs of infected animals, compared with the control group of infected but untreated animals.
- Below are examples of the preparation and use of an anti-RNA viral preparation (anti-RNA viral pharmaceutical composition), confirming but not limiting the present application.
- Example 1. Preparation of the anti-SARS-CoV-2/COVID-19 pharmaceutical composition (APC-1 - APC-3, PCL-2).
- APC-1. NIMR from Shanghai XingMo Biotechnology Co., Ltd., China (20.0 mg), and APR from Wanhua Biochem, China (37.0 mg, 200,000 KIU), with an activity of 5400 KIU mg were dissolved in saline (20 ml) under ultrasonic stirring for 5 minutes to yield 20 ml APC-1 containing NIMR (1.0 mg/ml) and APR (10,000) KIU/ml.
- APC-2 and PCL-2. 200.0 mg of NIMR from Shanghai XingMo Biotechnology Co., Ltd., China were dissolved in 10 ml GORDOX under ultrasonic stirring for 5 minutes to yield 10 ml APC-2 containing 20.0 mg/ml of NIMR and 10,000 KIU/ml of APR. The resulting APC-2 was lyophilized to give PCL-2 containing 200 mg NIMR and 100,000 KIU APR.
- APC-3. 100.0 mg of NIMR from Shanghai XingMo Biotechnology Co., Ltd., China were dissolved in 10 ml GORDOX + 90 ml saline under ultrasonic stirring for 5 minutes to yield 100 ml APC-3 containing 1.0 mg/ml of NIMR and 1,000 KIU/ml of APR.
- Example 2. Stability of APC-1. The stability of APC-1 was studied by UV spectroscopy on an Agilent 8453 spectrophotometer after storage under normal conditions (1) and under stress tests (after exposure for 24 hours in the light at 25° C. (2); after exposure for 48 hours in the dark at 3-5° C. (3); after exposure for 48 hours in the dark at 25° C. (4); and after exposure for 48 hours in the dark at 60° C. (5)). The optical densities of the maxima of the initial spectra (condition 1) APC-1 differ greatly from those in the stress test. The percentage of change in optical density under conditions 3-5 compared to optical density under Conditions 1 is > 2%. This indicates that APC-1 and APC-2 from are limitedly stable under rapid tests conditions and them must be used within a few hours after preparation.
- Example 3. A device for inhalation therapy and prevention of SARS-CoV-2 / COVID-19. 5 - 10 ml of APC-3 containing NIMR (1 mg/ml) and APR (1,000 KIU/ml) is placed into a compression nebulizer Omron NE-C300 Complete or in a portable ultrasonic Feellife Aerogo mesh nebulizer and is receive the device for inhalation therapy and prevention of SARS-CoV-2 / COVID-19.
- Example 4. Devices for nasal spray therapy and prevention of SARS-CoV-2 / COVID-19. 5 - 10 ml of APC 3 containing NIMR (1 mg/ml) and APR (1000 KIU/ml) is placed into a plastic can for nasal and is receive the device for nasal therapy and prevention of SARS-CoV-2 / COVID-19.
- Example 5. Treatment with APC-2 of transgenic mice infected with mouse-adapted SARS-CoV-2.
- In the experiment, 4 groups of transgenic mice (B6.Cg-Tg(K18-ACE2)2Prlmn/HEMI Hemizygous for Tg(K18-CE2)2Prlmn from Jackson Immuno-research, West Grove, PA, USA), females, age - 6-8 weeks, weighing 19-24 g, were formed, 4 animals per group.
- Group 1 - control group, untreated mice: on day 1 in the morning the mice were infected with SARS-CoV-2, and then 5 ml/kg of water for injection was intragastrical administered immediately after infection and in the evening of the same day.
- Group 2 - treatment with GORDOX® - 10 000 KIU/ml of APR. Dose: 50 000 KIU/kg APR.
- Groups 3 - treatment with saline solution of NIMR - 20 mg/ml. Dose: 100.0 mg/kg of NIMR.
- Groups 4 - treatment with the APC-2. Dose: 50 000 KIU/kg of APR + 100 mg/kg of NIMR.
- Treatment regimen for transgenic mice: parenteral (intraperitoneal) administration of drugs 2 times a day; day 0 - 1 hour before infected with mouse-adapted SARS-CoV-2 (“Dubrovka” strain, identification number GenBank: MW161041.1) and 6-8 hours after infection; days 1, 2, 3 - 2 times a day, for a total of 4 days (days 0, 1, 2, 3); Day 4 - lung sampling from all animals to assess the virus titer in the lungs, visual assessment of the lungs and transfer of the lungs for histology; days 0 -4 - daily assessment of body weight and condition of mice.
- On day 0, animals from all groups were infected with the SARS-CoV-2 “Dubrovka” virus (103.5 TCID50/ml). All mice were infected intranasally under light ether anesthesia in a volume of 30 µl for both nostrils.
- Euthanasia (painless killing of the animal) was carried out by the responsible person in accordance with the existing ethical requirements, by dislocation of the cervical vertebrae with preliminary anesthesia with ether. Euthanasia was performed promptly after the end of the experiments.
- On day 4 post-infection with the virus, the animals in each group were sacrificed and the lungs were removed under sterile conditions. One lung was fixed in formalin for further histology, the second lung was prepared to measure the virus titer. To do this, after washing three times in a solution of 0.01 M phosphate buffered saline (PBS), the lungs were homogenized and resuspended in 1 ml of cold sterile PBS. The suspension was cleared from cell debris by centrifugation at 2000 g for 10 min, and the supernatant was used to determine the infectious titer of the virus in cell culture and to perform PCR. The obtained samples were stored at -80° C. until the experiments were carried out.
- To determine the infectious titer of the virus from the lungs of mice, Vero CCL81 cells were seeded in 96-well Costar plates with an average density of 20,000 cells per well and grown in DMEM medium in the presence of 5% fetal calf serum, 10 mM glutamine and antibiotics (penicillin 100 IU/well). ml and streptomycin 100 µg/ml) until a complete monolayer is formed (within 3 days). Before infection with the virus, the cell culture was washed twice with DMEM medium without serum. 10-fold dilutions of each lung virus sample were prepared from 10-1 to 10-7. The prepared dilutions in a volume of 200 µL were added to cell culture plates and incubated in 5% CO2 at 37° C. for 5 days until a cytopathic effect (CPE) appeared in virus control cells. Accounting for the result of the manifestation of CPP in cells was carried out using a quantitative MTT test. The virus titer was calculated using the Ramakrishnan M.A formula in the Excel program [M.A. Ramakrishnan. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016, 5, 85-86. doi: 10.5501/wjv.v5.i2.85] and expressed as IgTCID50/ml (TCID50 - The median tissue culture infectious dose is defined as the dilution of a virus required to infect 50% of a given cell culture.) [I. Leneva et al. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses 2021, 13(8): 1665. doi: 10.3390/v13081665]. Next, the average titer value for samples from mice of the same group was calculated.
- The effectiveness of the drugs in a model of the transgenic mice infected with mouse-adapted SARS-CoV-2 was assessed according to decrease in the titer of the virus in the lungs of animals after 4 days.
- The obtained digital data were subjected to statistical processing in the “Statistica 8.0” software. The results are shown in Table 2.
-
TABLE 2 The effectiveness of the drugs and control (untreated mice) on the model the transgenic mice infected with mouse-adapted SARS-CoV-2. Group Dose of drug logTCID50/ml a Decrease in logTCID50/mL 1 Control 8.83; 9.50; 8.17; 8.5; 8.83 (8,77) 2 50000 KIU/kg APR 7.17; 6.50; 8.17; 7.17 (7,25) 1.52 3 100 mg/kg NIMR 6.17, 6.83, 6.83, 5.83 (6.42) 2.35 4 APC-2 (100 mg/kg NIMR + 50000 KIU/kg APR) 5.17, 5.50,5.50,5.50, 6.17 (5,57) 3.20 b % reduction in virus titer (logTCID50/ml) compared to control (group 1). - As can be seen from Table 2, parenteral (intraperitoneal) treatment of mice infected with SARS-CoV-2 resulted in a reduction in virus titer in the lungs of infected animals compared to a control group of infected but untreated animals. Thus, with parenteral monotherapy with APR or NIMR, a decrease in virus titer (logTCID50/ml) by 1.52 and 2.35, respectively, was observed. At the same time, combination parenteral therapy of APR + MOV provides a decrease in virus titer by 3.2 orders of magnitude.
- Example 6. Intravenous treatment of Syrian hamsters infected with the SARS-CoV-2 using the APC-2 containing NIMR and APR.
- The efficacy of the APC-2 of the present application was evaluated using a model of SARS-CoV-2 infection in Syrian hamsters [R. Boudewijns et al. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters. BioRxiv preprint. doi: https://doi.org/10.1101/2020.04.23.056838; this version posted Apr. 24, 2020. https://www.biorxiv.org/content/10.1101/2020.04.23.056838v1].
- The strain SARS-CoV-2 hCoV-19/Australia/VIC01/2020 was obtained from the State Research Center of Virology and Biotechnology VECTOR (Russia). The infectious virus was isolated by sequential passage in Vero E6 cells. The titer of the viral suspension was determined by endpoint dilution on Vero E6 cells using the Reed-Muench method. The work related to the live virus was carried out under isolated laboratory conditions that meet the international BSL-3 + VECTOR requirements.
- Vero E6 cells from VECTOR’s Collection of Cell Cultures were cultured in Minimum Essential Medium (MEM) (Gibco) supplemented with 10% fetal bovine serum (Integro), 1% L-glutamine (Gibco), and 1% Bicarbonate (Gibco). Endpoint titrations were performed with a medium containing 2% fetal bovine serum.
- Wild-type Syrian hamsters at the age of 6-10 months weighing 100-120 g from State Scientific Center for Virology and Biotechnology “Vector” of Rospotrebnadzor (Russia) were kept with unlimited access to food and water. Hamsters were randomized into 4 cohorts, 8 animals in each cohort (4 males and 4 females).
- Hamsters were anesthetized with zoletil-xyla and inoculated into each nostril with 50 µl anesthetic combination containing 103TCID50.
- Group 1 - control group, untreated hamsters. Dose: 5 ml/kg saline.
- Group 2 - treatment with GORDOX® - 10000 KIU/ml of APR. Dose: 10000 KIU/kg APR.
- Groups 3 - treatment with saline solution of NIMR - 20 mg/ml. Dose: 100.0 mg/kg of NIMR.
- Groups 4 - treatment with the APC-2 (NIMR - 20 mg/ml + 10000 KIU/ml of APR). Dose: 50 000 KIU/kg of APR + 100 mg/kg of NIMR.
- The drugs were injected under light isoflurane anesthesia intravenously, 2 times a day for 4 days, starting the first injection one hour before infection, 6 hours after infection, then for 3 days after 12 hours.
- Hamsters were checked daily for appearance, behavior and weight. On the 4th day after infection, the hamsters were euthanized by intravenous injection of 500 µl doletal (200 mg/ml sodium pentobarbital, Vétoquinol SA). Hamster lung tissues were harvested after sacrifice and homogenized using a Precellys homogenizer in a 350 µl RNeasy lysis buffer (RNeasy Mini kit, Qiagen) and centrifuged (10,000 rpm, 5 min) to remove cell debris. RNA was extracted according to the manufacturer’s instructions. Real-time PCR was performed on the LightCycler96 platform (Roche) using the iTaq Universal Probes One-Step RT-qPCR kit (BioRad) [R. Boudewijns et al. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters. BioRxiv preprint. doi: https://doi.org/10.1101/2020.04.23.056838; this version posted Apr. 24, 2020. https://www.biorxiv.org/content/10.1101/2020.04.23.056838v1].
- For histological analysis, lung tissue was fixed in 4% formaldehyde, embedded in paraffin, and stained with hematoxylin-eosin. Damage was assessed on a scale from 1 to 3: stagnation, intra-alveolar bleeding, apoptotic bodies in the bronchial epithelium, necrotic bronchiolitis, perivascular edema, bronchopneumonia, perivascular inflammation, peribronchial inflammation, and vascular inflammation.
- Statistical analysis was performed using the GraphPed Prism software from GraphPed Software, Inc. Statistical significance was determined using the Mann-Whitney nonparametric U-test. The values of P ≤ 0.05 were considered significant.
- An analysis of the results obtained showed that APC-2 comprising NIMR and APR demonstrated a high anti-SARS-CoV-2/COVID-19 efficacy. Thus, in comparison with the control group, after intravenous treatment of Syrian hamsters infected with the SARS-CoV-2 of drug APC-2, the titer of SARS CoV-2 in the tissues of the lungs decreased by more than an order of magnitude compared to the control group.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/298,056 US20230346899A1 (en) | 2022-03-31 | 2023-04-10 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/709,727 US11648300B1 (en) | 2022-03-31 | 2022-03-31 | Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19 |
US18/298,056 US20230346899A1 (en) | 2022-03-31 | 2023-04-10 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/709,727 Continuation US11648300B1 (en) | 2022-03-31 | 2022-03-31 | Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230346899A1 true US20230346899A1 (en) | 2023-11-02 |
Family
ID=86333768
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/709,727 Active US11648300B1 (en) | 2022-03-31 | 2022-03-31 | Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19 |
US18/298,056 Pending US20230346899A1 (en) | 2022-03-31 | 2023-04-10 | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/709,727 Active US11648300B1 (en) | 2022-03-31 | 2022-03-31 | Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19 |
Country Status (1)
Country | Link |
---|---|
US (2) | US11648300B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2738885C1 (en) * | 2020-04-30 | 2020-12-18 | Андрей Александрович Иващенко | Anti-sars-cov-2 viral agent antiprovir |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220233480A1 (en) * | 2020-03-23 | 2022-07-28 | Vicore Pharma Ab | Use of angiotensin ii type 2 receptor agonist |
EA202000347A1 (en) * | 2020-04-30 | 2021-11-30 | Андрей Александрович ИВАЩЕНКО | ANTI-SARS-CoV-2 VIRAL AGENT ANTIPROVIR |
JP2023539185A (en) * | 2020-08-21 | 2023-09-13 | アレクサンドル・バシリエビッチ・イワシェンコ | Anti-coronavirus agents and treatment methods for COVID-19 (SARS-CoV-2) combination therapy |
US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
US11884663B2 (en) * | 2020-12-04 | 2024-01-30 | Acer Therapeutics, Inc. | Solid forms of emetine |
AU2021409558A1 (en) * | 2020-12-22 | 2023-07-20 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
US20220196658A1 (en) * | 2020-12-23 | 2022-06-23 | University Of Washington | ANTI-VIRUS IgG3 BINDING ASSAY TO ASSESS VIRUS NEUTRALIZATION AND RELATED METHODS |
-
2022
- 2022-03-31 US US17/709,727 patent/US11648300B1/en active Active
-
2023
- 2023-04-10 US US18/298,056 patent/US20230346899A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11648300B1 (en) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2596785C2 (en) | Composition containing peptide and virus neuraminidase inhibitor | |
RU2554745C2 (en) | Recombinant human cc10 protein for treating influenza | |
WO2021207325A1 (en) | Natural extract and their components for use in mitigating acute respiratory distress syndrome | |
US20230346899A1 (en) | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + NIRMATRELVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDING COVID-19 | |
CN112386595A (en) | Pharmaceutical composition for treating viral infection of respiratory system | |
US20230158063A1 (en) | Airway epithelial alkaline therapy to treat viral respiratory infection | |
TWI792171B (en) | Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1 | |
CN112675175B (en) | Application of brigatinib in preparation of medicine for treating idiopathic pulmonary fibrosis | |
CN112386597B (en) | Application of zebritinib in preparation of medicine for treating pulmonary fibrosis diseases | |
WO2021221537A1 (en) | Sars-cov-2 antiviral drug antiprovir | |
Rasouli et al. | Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against COVID-19 | |
CN112675179A (en) | Application of Ivitinib in preparation of medicine for treating idiopathic pulmonary fibrosis | |
JP7399976B2 (en) | Medicines, foods, and their uses to prevent or treat COVID-19 novel coronavirus pneumonia | |
US20240000901A1 (en) | Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection | |
US20230310480A1 (en) | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + MOLNUPIRAVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | |
RU2738885C1 (en) | Anti-sars-cov-2 viral agent antiprovir | |
US20230310467A1 (en) | PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 | |
WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
US20230310544A1 (en) | ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG | |
CN112274520A (en) | Application of Rudesiwei in preparation of medicine for treating idiopathic pulmonary fibrosis | |
WO2023192779A2 (en) | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections | |
RU2772701C1 (en) | Methods for treating infectious diseases caused by coronavirus | |
RU2742116C1 (en) | Anti-coronavirus agent for covid-19 combination therapy (sars-cov-2) | |
US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
US20230226136A1 (en) | A synergistic formulation for management of respiratory pathogens including coronaviruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SAVCHUK, NIKOLAY FILIPPOVICH, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVACHTCHENKO, ALEXANDRE VASILIEVICH;IVASHCHENKO, ANDREY ALEXANDROVICH;IVACHTCHENKO, ALENA ALEXANDROVNA;AND OTHERS;REEL/FRAME:063277/0971 Effective date: 20220321 Owner name: IVACHTCHENKO, ALENA ALEXANDROVNA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVACHTCHENKO, ALEXANDRE VASILIEVICH;IVASHCHENKO, ANDREY ALEXANDROVICH;IVACHTCHENKO, ALENA ALEXANDROVNA;AND OTHERS;REEL/FRAME:063277/0971 Effective date: 20220321 Owner name: IVACHTCHENKO, ALEXANDRE VASILIEVICH, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVACHTCHENKO, ALEXANDRE VASILIEVICH;IVASHCHENKO, ANDREY ALEXANDROVICH;IVACHTCHENKO, ALENA ALEXANDROVNA;AND OTHERS;REEL/FRAME:063277/0971 Effective date: 20220321 Owner name: ASAVI LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IVACHTCHENKO, ALEXANDRE VASILIEVICH;IVASHCHENKO, ANDREY ALEXANDROVICH;IVACHTCHENKO, ALENA ALEXANDROVNA;AND OTHERS;REEL/FRAME:063277/0971 Effective date: 20220321 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |